{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274094","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.629906+00:00","generated_at":"2026-06-08T07:25:49.200279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Disc Medicine Q3 net loss $14.1M; bitopertin Phase 2 enrollment complete","bullets":["Cash $370.5M as of Sep 30, 2023; expected to fund operations into 2026.","Completed enrollment for BEACON (open-label) and AURORA (placebo-controlled) Phase 2 trials of bitopertin in EPP/XLP.","Updated BEACON data including pivotal endpoint (cumulative time in sunlight) to be presented at ASH 2023.","Initiated Phase 1 trial of DISC-3405 for PV; received FDA fast track designation.","R&D expenses $14.4M (up from $7.9M YoY) driven by portfolio progression and headcount."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274094","json":"https://secwatch.observer/filing/0001193125-23-274094.json","markdown":"https://secwatch.observer/filing/0001193125-23-274094.md","text":"https://secwatch.observer/filing/0001193125-23-274094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/0001193125-23-274094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/d594333d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:25:49.200279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d3495fa80d00778465e40ffd3b0940d3e04ab2c","claim":"Disc Medicine, Inc. reported third quarter ended September 30, 2023 results: net income Net loss was $14.1 million.","evidence_excerpt":"• Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523274094/0001193125-23-274094-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $14.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}